Enhanced Implantable Biotherapeutic Agent Delivery System
Legal Citation
Summary of the Inventive Concept
An advanced nanoporous canister with a bicontinuous morphology for delivering biotherapeutic agents, enhancing cell survival and promoting tissue repair in mammalian hosts.
Background and Problem Solved
The original implantable cellular and biotherapeutic agent delivery canister patent had limitations in terms of cell survival, surface area exposure, and biocompatibility. The new inventive concept addresses these limitations by introducing a bicontinuous morphology, surface treatment patterns, and coatings to improve the device's performance and safety.
Detailed Description of the Inventive Concept
The enhanced system consists of a nanoporous canister with a bicontinuous morphology, designed to wholly isolate a therapeutically active agent and/or cells therein. The canister features a rigid, nanoporous structure with two nanoscale through-porous regions, allowing for diffusion of therapeutic metabolites and nutrients/waste products. A surface treatment pattern increases the surface area of exposure, while a coating reduces inflammation and promotes tissue integration. The system can be monitored using a sensor to detect changes in therapeutic metabolite concentrations.
Novelty and Inventive Step
The new claims introduce the bicontinuous morphology, surface treatment patterns, and coatings, which are not present in the original patent. These innovations provide a significant improvement in cell survival, biocompatibility, and overall device performance.
Alternative Embodiments and Variations
Alternative embodiments could include modifying the nanoporous structure's geometry, using different materials for the coating, or integrating additional sensors for real-time monitoring. Variations could also involve adapting the device for different therapeutic applications or target tissues.
Potential Commercial Applications and Market
The enhanced implantable biotherapeutic agent delivery system has significant commercial potential in the fields of regenerative medicine, tissue engineering, and biomedical devices. Target industries include pharmaceutical companies, medical device manufacturers, and research institutions focused on developing novel therapies for various diseases and conditions.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K9/0024 |
| A | A61 | A61F2/022 |
| A | A61 | A61K31/337 |
| A | A61 | A61K31/397 |
| A | A61 | A61K31/436 |
| A | A61 | A61K31/65 |
| A | A61 | A61K31/7036 |
| A | A61 | A61K35/28 |
| A | A61 | A61K38/14 |
| A | A61 | A61K38/1866 |
| A | A61 | A61K38/22 |
| A | A61 | A61K39/395 |
| A | A61 | A61K47/02 |
| A | A61 | A61M39/0247 |
| A | A61 | A61M2039/027 |
| A | A61 | A61M2039/0261 |
| A | A61 | A61M2039/0276 |
| A | A61 | A61M2205/04 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Biomedical engineering, specifically implantable medical devices for cellular and biotherapeutic agent delivery, with expertise in nanoporous materials, surface engineering, and tissue integration technologies
Person of Ordinary Skill (PHOSITA) Profile
A biomedical engineer or materials scientist with advanced degree, working knowledge of nanoscale fabrication techniques, cellular encapsulation methods, and biomedical device design, familiar with strategies for improving implantable device performance and biocompatibility
Obviousness Rationale
A person having ordinary skill would recognize that the PTD's variations represent predictable engineering improvements to the source patent's fundamental nanoporous implantable device concept. The bicontinuous morphology, surface treatment patterns, and monitoring capabilities are logical extensions of the original device's core functionality of isolating and delivering therapeutic agents. These modifications represent standard design optimization strategies well within a skilled practitioner's capabilities.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,672 |
|---|---|
| Title | Implantable cellular and biotherapeutic agent delivery canister |
| Assignee(s) | NanoVault Medical LLC |